Condition: High Risk Pregnancy · Pregnancy Complications · Antiphospholipid Syndrome in Pregnancy · Sponsor: David Ware Branch
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.
This description comes directly from the study's public registry record.
Rose Peckham · 801-585-7617 · Rose.Peckham@hsc.utah.edu
Elizabeth Turner · 801-585-0591 · elizabeth.e.turner@hsc.utah.edu
Always discuss trial participation with your own doctor first.
| Hospital for Special Surgery | New York, New York, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| TRIO Advancing Reproductive Care | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03152058